New FDA bioavailability guidance [BE/BA News]

posted by wienui  – Germany/Oman, 2022-04-15 11:44 (1156 d 17:20 ago) – Posting: # 22932
Views: 4,943

Dear All,

Yesterday, on 14 April, The US Food and Drug Administration (FDA) published final guidance on the bioavailability (BA) data drug sponsors should include in their premarket investigational new drug (IND) applications, new drug applications (NDA), and NDA supplements.

The guidance has been several years in the making after garnering significant feedback from the industry, which the agency says it has addressed in the latest version.

https://www.fda.gov/media/121311/download.

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
16 visitors (0 registered, 16 guests [including 15 identified bots]).
Forum time: 05:05 CEST (Europe/Vienna)

To call the statistician after the experiment is done
may be no more than asking him to perform a postmortem examination:
he may be able to say what the experiment died of.    R.A. Fisher

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5